{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:08:13Z","timestamp":1790676493536,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2023,3,30]]},"DOI":"10.1038\/s41416-022-02129-2","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T15:02:21Z","timestamp":1674313341000},"page":"1377-1390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immunoproteasome inhibition prevents progression of castration-resistant prostate cancer"],"prefix":"10.1038","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0891-4328","authenticated-orcid":false,"given":"Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianli","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9428-2349","authenticated-orcid":false,"given":"Michael","family":"Basler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,21]]},"reference":[{"key":"2129_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"2129_CR2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","volume":"77","author":"S Gillessen","year":"2020","unstructured":"Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, et al. Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019. Eur Urol. 2020;77:508\u201347.","journal-title":"Eur Urol"},{"key":"2129_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nrc801","volume":"2","author":"SR Denmeade","year":"2002","unstructured":"Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;2:389\u201396.","journal-title":"Nat Rev Cancer"},{"key":"2129_CR4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pr. 2011;65:1180\u201392.","journal-title":"Int J Clin Pr"},{"key":"2129_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2017.08.035","volume":"74","author":"K Miller","year":"2018","unstructured":"Miller K, Carles J, Gschwend JE, Van Poppel H, Diels J, Brookman-May SD. The phase 3 COU-AA-302 study of abiraterone acetate plus prednisone in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: stratified analysis based on pain, prostate-specific antigen, and gleason score. Eur Urol. 2018;74:17\u201323.","journal-title":"Eur Urol"},{"key":"2129_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","volume":"71","author":"TM Beer","year":"2017","unstructured":"Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71:151\u20134.","journal-title":"Eur Urol"},{"key":"2129_CR7","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383:2345\u201357.","journal-title":"N Engl J Med"},{"key":"2129_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-3-319-95693-0_3","volume":"1095","author":"AK Tewari","year":"2018","unstructured":"Tewari AK, Stockert JA, Yadav SS, Yadav KK, Khan I. Inflammation and prostate cancer. Adv Exp Med Biol. 2018;1095:41\u201365.","journal-title":"Adv Exp Med Biol"},{"key":"2129_CR9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/pros.22805","volume":"74","author":"Q Zhang","year":"2014","unstructured":"Zhang Q, Liu S, Zhang Q, Xiong Z, Wang AR, Myers L, et al. Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment. Prostate. 2014;74:869\u201379.","journal-title":"Prostate"},{"key":"2129_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","volume":"559","author":"A Calcinotto","year":"2018","unstructured":"Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018;559:363\u20139.","journal-title":"Nature"},{"key":"2129_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.cell.2011.12.030","volume":"148","author":"EM Huber","year":"2012","unstructured":"Huber EM, Basler M, Schwab R, Heinemeyer W, Kirk CJ, Groettrup M, et al. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell. 2012;148:727\u201338.","journal-title":"Cell"},{"key":"2129_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nri2687","volume":"10","author":"M Groettrup","year":"2010","unstructured":"Groettrup M, Kirk CJ, Basler M. Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol. 2010;10:73\u20138.","journal-title":"Nat Rev Immunol"},{"key":"2129_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1084\/jem.187.1.97","volume":"187","author":"TA Griffin","year":"1998","unstructured":"Griffin TA, Nandi D, Cruz M, Fehling HJ, Kaer LV, Monaco JJ, et al. Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med. 1998;187:97\u2013104.","journal-title":"J Exp Med"},{"key":"2129_CR14","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.4049\/jimmunol.1201183","volume":"189","author":"KW Kalim","year":"2012","unstructured":"Kalim KW, Basler M, Kirk CJ, Groettrup M. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol. 2012;189:4182\u201393.","journal-title":"J Immunol"},{"key":"2129_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nm.1978","volume":"15","author":"T Muchamuel","year":"2009","unstructured":"Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med. 2009;15:781\u20137.","journal-title":"Nat Med"},{"key":"2129_CR16","doi-asserted-by":"publisher","first-page":"634","DOI":"10.4049\/jimmunol.0903182","volume":"185","author":"M Basler","year":"2010","unstructured":"Basler M, Dajee M, Moll C, Groettrup M, Kirk CJ. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol. 2010;185:634\u201341.","journal-title":"J Immunol"},{"key":"2129_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/emmm.201303543","volume":"6","author":"M Basler","year":"2014","unstructured":"Basler M, Mundt S, Muchamuel T, Moll C, Jiang J, Groettrup M, et al. Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med. 2014;6:226\u201338.","journal-title":"EMBO Mol Med"},{"key":"2129_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/art.33333","volume":"64","author":"HT Ichikawa","year":"2012","unstructured":"Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum. 2012;64:493\u2013503.","journal-title":"Arthritis Rheum"},{"key":"2129_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1365-2249.2012.04578.x","volume":"168","author":"Y Nagayama","year":"2012","unstructured":"Nagayama Y, Nakahara M, Shimamura M, Horie I, Arima K, Abiru N. Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto\u2019s thyroiditis, but not for Graves\u2019 hyperthyroidism, in mice. Clin Exp Immunol. 2012;168:268\u201373.","journal-title":"Clin Exp Immunol"},{"key":"2129_CR20","doi-asserted-by":"publisher","first-page":"50873","DOI":"10.18632\/oncotarget.15141","volume":"8","author":"J Koerner","year":"2017","unstructured":"Koerner J, Brunner T, Groettrup M. Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice. Oncotarget. 2017;8:50873\u201388.","journal-title":"Oncotarget"},{"key":"2129_CR21","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.kint.2017.09.023","volume":"93","author":"J Li","year":"2018","unstructured":"Li J, Basler M, Alvarez G, Brunner T, Kirk CJ, Groettrup M. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation. Kidney Int. 2018;93:670\u201380.","journal-title":"Kidney Int"},{"key":"2129_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1172\/JCI122367","volume":"129","author":"B Song","year":"2019","unstructured":"Song B, Park SH, Zhao JC, Fong KW, Li S, Lee Y, et al. Targeting FOXA1-mediated repression of TGF-\u03b2 signaling suppresses castration-resistant prostate cancer progression. J Clin Invest. 2019;129:569\u201382.","journal-title":"J Clin Invest"},{"key":"2129_CR23","doi-asserted-by":"publisher","first-page":"e46512","DOI":"10.15252\/embr.201846512","volume":"19","author":"M Basler","year":"2018","unstructured":"Basler M, Lindstrom MM, LaStant JJ, Bradshaw JM, Owens TD, Schmidt C, et al. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity. EMBO Rep. 2018;19:e46512.","journal-title":"EMBO Rep."},{"key":"2129_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.kint.2018.10.022","volume":"95","author":"J Li","year":"2019","unstructured":"Li J, Koerner J, Basler M, Brunner T, Kirk CJ, Groettrup M. Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors. Kidney Int. 2019;95:611\u201323.","journal-title":"Kidney Int"},{"key":"2129_CR25","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/onc.2016.240","volume":"36","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Liu S, Parajuli KR, Zhang W, Zhang K, Mo Z, et al. Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. Oncogene. 2017;36:687\u201399.","journal-title":"Oncogene"},{"key":"2129_CR26","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.3390\/cells10113216","volume":"10","author":"M Basler","year":"2021","unstructured":"Basler M, Groettrup M. On the role of the immunoproteasome in protein homeostasis. Cells. 2021;10:3216.","journal-title":"Cells"},{"key":"2129_CR27","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1126\/science.1209038","volume":"334","author":"P Walter","year":"2011","unstructured":"Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011;334:1081\u20136.","journal-title":"Science"},{"key":"2129_CR28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrd3976","volume":"12","author":"C Hetz","year":"2013","unstructured":"Hetz C, Chevet E, Harding HP. Targeting the unfolded protein response in disease. Nat Rev Drug Disco. 2013;12:703\u201319.","journal-title":"Nat Rev Drug Disco"},{"key":"2129_CR29","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1080\/03007995.2017.1341869","volume":"33","author":"N Summers","year":"2017","unstructured":"Summers N, Vanderpuye-Orgle J, Reinhart M, Gallagher M, Sartor O. Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature. Curr Med Res Opin. 2017;33:1995\u20132008.","journal-title":"Curr Med Res Opin"},{"key":"2129_CR30","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3389\/fimmu.2018.01786","volume":"9","author":"AR Elia","year":"2018","unstructured":"Elia AR, Caputo S, Bellone M. Immune checkpoint-mediated interactions between cancer and immune cells in prostate adenocarcinoma and melanoma. Front Immunol. 2018;9:1786.","journal-title":"Front Immunol"},{"key":"2129_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","volume":"38","author":"P Sharma","year":"2020","unstructured":"Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell. 2020;38:489\u201399.","journal-title":"Cancer Cell"},{"key":"2129_CR32","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/pros.23343","volume":"77","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Liu S, Ge D, Cunningham DM, Huang F, Ma L, et al. Targeting Th17-IL-17 pathway in prevention of micro-invasive prostate cancer in a mouse model. Prostate. 2017;77:888\u201399.","journal-title":"Prostate"},{"key":"2129_CR33","doi-asserted-by":"publisher","first-page":"11127","DOI":"10.1021\/acs.jmedchem.8b01201","volume":"61","author":"HWB Johnson","year":"2018","unstructured":"Johnson HWB, Lowe E, Anderl JL, Fan A, Muchamuel T, Bowers S, et al. Required immunoproteasome subunit inhibition profile for anti-inflammatory efficacy and clinical candidate KZR-616 ((2 S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide). J Med Chem. 2018;61:11127\u201343.","journal-title":"J Med Chem"},{"key":"2129_CR34","doi-asserted-by":"publisher","first-page":"50447","DOI":"10.18632\/oncotarget.14579","volume":"8","author":"N Vachharajani","year":"2017","unstructured":"Vachharajani N, Joeris T, Luu M, Hartmann S, Pautz S, Jenike E, et al. Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7. Oncotarget. 2017;8:50447\u201359.","journal-title":"Oncotarget"},{"key":"2129_CR35","doi-asserted-by":"publisher","first-page":"7319","DOI":"10.1002\/jcb.27030","volume":"119","author":"J Sha","year":"2018","unstructured":"Sha J, Han Q, Chi C, Zhu Y, Pan J, Dong B, et al. PRKAR2B promotes prostate cancer metastasis by activating Wnt\/\u03b2-catenin and inducing epithelial-mesenchymal transition. J Cell Biochem. 2018;119:7319\u201327.","journal-title":"J Cell Biochem"},{"key":"2129_CR36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/978-3-030-32656-2_16","volume":"1210","author":"Y Yeh","year":"2019","unstructured":"Yeh Y, Guo Q, Connelly Z, Cheng S, Yang S, Prieto-Dominguez N, et al. Wnt\/Beta-catenin signaling and prostate cancer therapy resistance. Adv Exp Med Biol. 2019;1210:351\u201378.","journal-title":"Adv Exp Med Biol"},{"key":"2129_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10555-008-9169-0","volume":"28","author":"M Yilmaz","year":"2009","unstructured":"Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15\u201333.","journal-title":"Cancer Metastasis Rev"},{"key":"2129_CR38","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2003.02.083","volume":"21","author":"SP Balk","year":"2003","unstructured":"Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003;21:383\u201391.","journal-title":"J Clin Oncol"},{"key":"2129_CR39","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.biopha.2018.02.067","volume":"101","author":"A Thakur","year":"2018","unstructured":"Thakur A, Roy A, Ghosh A, Chhabra M, Banerjee S. Abiraterone acetate in the treatment of prostate cancer. Biomed Pharmacother. 2018;101:211\u20138.","journal-title":"Biomed Pharmacother"},{"key":"2129_CR40","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.cell.2013.01.037","volume":"152","author":"JA Nathan","year":"2013","unstructured":"Nathan JA, Spinnenhirn V, Schmidtke G, Basler M, Groettrup M, Goldberg AL. Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell. 2013;152:1184\u201394.","journal-title":"Cell"},{"key":"2129_CR41","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1136\/annrheumdis-2018-213289","volume":"77","author":"J Lickliter","year":"2018","unstructured":"Lickliter J, Bomba D, Anderl J, Fan A, Kirk CJ, Wang J. AB0509 Kzr-616, a selective inhibitor of the immunoproteasome, shows a promising safety and target inhibition profile in a phase I, double-blind, single (SAD) and multiple ascending dose (MAD) study in healthy volunteers. Ann Rheum Dis. 2018;77:1413\u20134.","journal-title":"Ann Rheum Dis"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02129-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02129-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02129-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T14:05:00Z","timestamp":1680012300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02129-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,21]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,3,30]]}},"alternative-id":["2129"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-02129-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,21]]},"assertion":[{"value":"28 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of Chongqing University Cancer Hospital and performed in accordance with the Declaration of Helsinki for human subject protection. No personal information of patients was involved.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the figures are original data from our institutions and they can be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}